派姆单抗在非小细胞肺癌治疗中的研究进展

Research Progress of Pembrolizumab in the Treatment of Non-small Cell Lung Cancer

摘要: 近年来，程序性死亡受体-1（programmed cell death-1，PD-1）抑制剂派姆单抗（Pembrolizumab）在非小细胞肺癌（non-small cell lung cancer，NSCLC）的治疗中显示出良好的疗效。2015年10月，派姆单抗获得美国FDA快速审批，用于治疗程序性死亡配体-1（programmed cell death-L1，PD-L1）阳性且在其他治疗后疾病进展的转移性NSCLC。随着临床试验的开展，派姆单抗在NSCLC治疗中的适用范围逐渐扩大，本文对派姆单抗治疗NSCLC的临床研究现状进行综述。

Abstract: In recent years, Pembrolizumab, a programmed death-1(PD-1) inhibitor has shown considerable responses and good tolerance in the treatment of non-small cell lung cancer (NSCLC). In October 2015, Pebrolizumab was approved by FDA for the treatment of metastatic NSCLC with PD-L1 positive and disease progression after other treatments. With the development of clinical trials, the applications of Pembrolizumab in NSCLC treatment have gradually expanded. In this review, we summarized the current clinical status of Pembrolizumab in the treatment of NSCLC.